Suppr超能文献

基于网络药理学和临床相关性的预测,探讨中药对 IV 期肺腺癌患者的有效成分和潜在靶点。

Network pharmacology-based and clinically relevant prediction of active ingredients and potential targets of Chinese herbs on stage IV lung adenocarcinoma patients.

机构信息

Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huan-Hu-Xi Road, Ti-Yuan-Bei, He-Xi District, Tianjin, 300060, China.

Department of Rheumatology, Tianjin Medical University General Hospital, Tianjin, China.

出版信息

J Cancer Res Clin Oncol. 2021 Jul;147(7):2079-2092. doi: 10.1007/s00432-020-03488-0. Epub 2021 Apr 2.

Abstract

AIM

This study is designed to ascertain the relative molecular targets of effective Chinese herbs in treating stage IV lung adenocarcinoma based on clinical data and network pharmacology. In addition, we showed that Chinese Herbal Medicine (CHM) treatment was associated with survival benefit for patients with stage IV lung adenocarcinoma and identified 18 herbs beneficial to survival through correlation analysis.

BACKGROUND

Increasing evidence has shown that CHM has efficient therapeutic effects for advanced lung adenocarcinoma, while active ingredients and potential targets remain unclear.

METHODS

Kaplan-Meier method and Cox regression analysis were used to evaluate the survival benefit of CHM treatment, and correlation analysis was applied to identify the most effective components in the formulas. A network pharmacological approach was used to decipher the potential therapeutic mechanisms of CHM.

RESULTS

CHM treatment was an independent protective factor. The hazard ratio (HR) was 0.487 (95% CI 0.293-0.807; P = 0.005). Patients in the CHM group had a longer median survival time (31 months) compared with the non-CHM group (19 months; P < 0.001). 18 out of the total 241 herbs were significantly correlated with favorable survival outcomes (P < 0.05), likely representing the most effective components in these formulas. Bioinformatics analysis suggested that the 18 herbs realize anti-lung-adenocarcinoma activity mainly through (1) inhibiting the activity of some growth factors' receptors, such as HGFR, EGFR, and IGFR. (2) Suppressing angiogenesis not only through VEGFR and PDGFR, but also through the function of neurotransmitters such as dopamine and serotonin. (3) Inhibiting the Ras signaling pathway directly through Ras as well as through ALK and FNTA/FNTB.

CONCLUSIONS

We performed a network pharmacological method to decipher the underlying mechanisms, which provides a good foundation for herbal research based on clinical data.

摘要

目的

本研究旨在基于临床数据和网络药理学,确定治疗Ⅳ期肺腺癌的有效中药的相对分子靶标。此外,我们还表明,中药(CHM)治疗与Ⅳ期肺腺癌患者的生存获益相关,并通过相关分析确定了 18 种有益于生存的草药。

背景

越来越多的证据表明,CHM 对晚期肺腺癌具有有效的治疗作用,而活性成分和潜在靶点仍不清楚。

方法

采用 Kaplan-Meier 法和 Cox 回归分析评估 CHM 治疗的生存获益,并应用相关分析确定配方中最有效的成分。采用网络药理学方法破译 CHM 的潜在治疗机制。

结果

CHM 治疗是独立的保护因素。危险比(HR)为 0.487(95%CI 0.293-0.807;P=0.005)。与非 CHM 组相比,CHM 组患者的中位生存时间更长(31 个月)(19 个月;P<0.001)。241 种草药中共有 18 种与良好的生存结果显著相关(P<0.05),可能代表这些配方中最有效的成分。生物信息学分析表明,18 种草药主要通过以下方式实现抗肺癌活性:(1)抑制某些生长因子受体的活性,如 HGFR、EGFR 和 IGFR。(2)不仅通过 VEGFR 和 PDGFR,还通过多巴胺和 5-羟色胺等神经递质的功能来抑制血管生成。(3)直接通过 Ras 以及通过 ALK 和 FNTA/FNTB 抑制 Ras 信号通路。

结论

我们采用网络药理学方法对其潜在机制进行破译,为基于临床数据的草药研究提供了良好的基础。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验